Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKai ShenHLHe LiCHChuan He

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows treatment discontinuation in CLL patients on zanubrutinib is infrequent, indicating the need to address economic barriers.

Key Points

  • The study aims to assess the real-world outcomes of zanubrutinib monotherapy in CLL/SLL patients regarding treatment discontinuation and persistence.
  • Retrospective observational study conducted at West China Hospital, focusing on adult CLL/SLL patients on zanubrutinib treatment.
  • Data collected on treatment duration, discontinuation reasons, dose reductions, and event-free survival rates.
  • Follow-up was conducted until March 1, 2025, including patients treated from December 2020 to April 2024.
  • 91 adult patients were enrolled; 39.6% received zanubrutinib as first line treatment.
  • 18.7% of patients discontinued treatment, primarily due to economic or personal reasons.
  • The median time on zanubrutinib before discontinuation was 8 months, with a 48-month estimated event-free survival rate of 77%.

Cite This Study

Shen et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d520https://doi.org/10.1182/blood-2025-7433
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort2026 · 4 citations
  2. 2Real-world treatment patterns and outcomes of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic leukemia (CLL/SLL).2024 · 2 citations
  3. 3Real-world chronic lymphocytic leukemia/small lymphocytic lymphoma treatment patterns at Florida cancer specialists & research institute among patients receiving zanubrutinib immediately following prior BTKi therapy2025
  4. 4Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy2025 · 1 citations
  5. 5Real‐World Treatment Patterns and Outcomes of Zanubrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (<scp>CLL</scp>/<scp>SLL</scp>)2025 · 2 citations